Lung cancer trial: adding chemo to targeted pill may buy more time
NCT ID NCT04769388
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolls 80 patients whose cancer DNA is still found in their blood after 3 weeks of osimertinib. The main goal is to see if the combination delays cancer growth longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib plus carboplatin and pemetrexed (chemotherapy)
- What this could lead to
- If successful, this could show that adding chemotherapy to osimertinib helps control lung cancer longer in patients whose cancer DNA remains detectable early on.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 80 participants, so results may not apply to all patients. Adding chemotherapy also increases side effects like fatigue, low blood counts, and nausea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.